A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.
Powell M, Filiaci V, Hensley M, Huang H, Moore K, Tewari K, Copeland L, Secord A, Mutch D, Santin A, Richards W, Warshal D, Spirtos N, Disilverstro P, Ioffe O, Miller D. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. Journal Of Clinical Oncology 2019, 37: 5500-5500. DOI: 10.1200/jco.2019.37.15_suppl.5500.Peer-Reviewed Original ResearchQuality of lifeOverall survivalEligible ptsRandomized phase 3 trialSimilar QOLStratified log-rank testAggressive epithelial malignancyNew standard regimenNRG Oncology trialsStages I-IVbChemotherapy-naive patientsPhase 3 trialLog-rank testPhase 2 activityGenitourinary hemorrhageNeurotoxicity scoresO cohortRecurrent carcinosarcomaPrimary endpointStandard regimenLonger PFSHazard ratioOptimal therapyGynecologic carcinosarcomaEpithelial malignancies